Aethlon Stockholders Approve 10x Authorized Share Increase and New Preferred Stock

summarizeSummary

Aethlon Medical stockholders approved a 10x increase in authorized common shares to 200 million, greenlit warrant and future financing issuances, and expanded the equity plan at the October 1 annual meeting; a proposal to authorize 20 million preferred shares failed.

check_boxKey Events · Corporate Governance and Compliance · AEMD

• New · Oct 5 · SEC 8-K/A

  Annual Meeting Record Date and Outstanding Shares

  The record date for the Annual Meeting was August 10, 2026, and 711,136 shares were outstanding and entitled to vote on the record date.

• New · Oct 5 · SEC 8-K/A

  Proposed Preferred Stock Par Value

  The proposed preferred stock had a par value of $0.001 per share.

• Updated · Oct 5 · SEC 8-K/A

  Preferred Stock Authorization Fails

  Stockholders did not approve authorizing 20,000,000 shares of preferred stock with terms to be set by the board. Proposal 7 received 204,122 votes for, below the required 355,569 majority of outstanding shares, with 9,529 votes against, 1,555 abstentions, and 184,547 broker non-votes.

• Authorized Common Shares Increased 10x

  Stockholders approved increasing authorized common stock from 20,000,000 to 200,000,000 shares, giving the board substantial flexibility for future equity issuances.

• Warrant Share Issuance Approved

  Stockholders approved issuance of up to 1,126,602 common shares upon exercise of Common Warrants and Placement Agent Warrants from the July 2026 offering.

• Future Financings Pre-Approved

  Stockholders approved future private financing transactions and warrant exercise inducement transactions, providing advance authorization for capital raises.

auto_awesomeAnalysis · AEMD · Industrial Applications And Services

Stockholders approved a massive expansion of Aethlon's authorized common capital — common shares jump from 20 million to 200 million. This gives the board enormous flexibility to issue equity, including for the pending North Immunology reverse merger and the $180M PIPE. The approval also covers 1.13 million warrant shares from the July offering and future private financings. However, the proposal to authorize 20 million new preferred shares failed, receiving 204,122 votes for, below the required 355,569 majority of outstanding shares. For a company with a market cap around $10.6 million, this authorization is highly dilutive if fully utilized, but it is a necessary step to complete the merger and secure financing.